







Program International HBV meeting 2025 – Berlin

Monday, September 8, 2025

08:00 – 12:00 Emerging Researchers Workshop*

08:00 - 08:30 Registration, breakfast, networking and icebreaker challenge

08:30 – 08:40 Welcome and Overview of Workshop

Chari Cohen, DrPH, MPH, Barbara Testoni, PhD, HDR and Dr. rer. nat. Lena Allweiss

08:40 - 09:00 Icebreaker Session

Thomas Tu, PhD

09:00-10:00 Keynote Address: "Why and How to Scicomm – Communicating Science to Nonexpert Audiences"

Ulrike Brandt-Bohne, PhD

10:00 – 10:30 Networking and Practice Session: The Elevator Speech

10:30 – 11:30 Table Discussion: Communicating Science in Different Settings

11:30 – 12:30 Putting It into Practice: Communicating your Research

12:30 – 13:30 Lunch and networking for Emerging Researchers Workshop

13:30 Conclusion

*Please note the Emerging Researchers Workshop is a ticketed event.

14:00-15:35 HBF and ICE-HBV Community Forum

14:00 – 14:05 Welcome and Opening Remarks

14:05 – 14:20 Current Hepatitis B Treatment Landscape in Germany

National Strategies - Hep B United: A national coalition for eliminating hepatitis B

Prof. Frank Tacke, MD, PhD Charité, Universitatsmedizin Berlin

14:20 – 14:35 Current Hepatitis Delta Treatment Landscape in Germany

Prof. Heiner Wedemeyer, MD, PhD, Hannover Medical School

14:35 – 14:50 Epidemiology, Progress and Challenges with Hepatitis B and D Elimination in Germany

Prof. Thomas Berg, MD, FAASLD, University of Leipzig Medical Center

14:50 – 15:20 Lived Experience of Hepatitis B or D in the European Region – Panel

Discussion

Moderator: Thomas Tu, PhD, Westmead Institute for Medical Research









Panel members from the European region will share their experiences of living with hepatitis B/D

15:20 - 15:25 Q&A

Moderated by Chari Cohen, DrPH, MPH

15:25 - 15:35 HepBCommunity.org Award Presentations

Presented by Thomas Tu, PhD

15:35 Closing Remarks

Prof. Maura Dandri, PhD, Chair ICE-HBV

16:00 – 16:30 Welcome address by co-organizers

Co-organizers: **Dr. rer. nat. Lena Allweiss** Research Scientist and Principal Investigator, University Medical Center Hamburg-Eppendorf, Hamburg, Germany and **Barbara Testoni, PhD, HDR** Team Leader - PathLiv Unit, Lyon University, Inserm, The Lyon

Hepatology Institute, Lyon, France

16:30 – 17:00 Distinguished Award in Hepatitis B Research Lecture – John M. Taylor, PhD

17:00 – 18:30 Session I: Emerging Models and Technologies

Chaired by: Rob Schwarz (USA) and Helene Strick Marchand (France)

17:00-17:10: An alphavirus replicon-based method enables high-throughput studies of HBV core variants

Catherine Freije

17:10 - 17:15 Q&A

17:15 – 17:25 A Syrian hamster model of persistent HDV infection

Elias Broeckhoven

17:25 - 17:30 Q&A

17:30 – 17:40 Cross-Species Core Protein Chimerism Enables HBV cccDNA Formation in

Murine Hepatocytes

Kaitao Zhao

17:40 - 17:45 Q&A

17:45 – 17:55: Domestic cat hepatocytes support NTCP-dependent HBV infection whereas

domestic cat hepadnavirus fails to infect human hepatocytes

Qingyan Wu

17:55-18:00 Q&A

18:00-18:10 Screening of RNA-based antiviral gene editors targeting HBV cccDNA using a novel episomal, stable HBV replicon system









Pratik Mallick

18:10 - 18:15 Q&A

18:15 – 18:25 Modeling HIV/HBV Co-Infection in Primary Human Cells

Adriana Norris

18:25 - 18:30 Q&A

18:30 – 20:30 Welcome Reception and Poster Viewing with drinks and food

Tuesday, September 9, 2025

08:30 – 09:00 Introduction I: Molecular Virology

Yuchen Xia (China)

09:00 – 10:00 Session II: Profiling intrahepatic complexity

Chaired by: Aleksei Suslov (Switzerland) and Xiaonan Zhang (Australia)

9:00-9:10: Spatial and quantitative profiling of intrahepatic HBsAg heterogeneity in chronic hepatitis B virus infection

Yuyan Qian

9:10 - 9:15 Q&A

9:15-9:25 Single cell laser capture microdissection (scLCM) and droplet digital PCR (ddPCR) reveal heterogeneity of HDV in six HBV/HDV co-infected people

Chi-Fen Lee

9:25 - 9:30 Q&A

9:30-9:40 High-throughput pipeline detecting viral integration reveals evidence for oncogenic insertional mutagenesis in domestic cat hepatitis B virus-associated hepatocellular carcinoma

Harout Ajoyan

9:40 - 9:45 Q&A

9:45 – 9:55 Comprehensive mapping of episomal and integrated hepatitis B genomes uncovers heterogeneous transcripts and drug-resistant lineages.

James Harris

9:55 - 10:00 Q&A

10:00 - 10:30 **Coffee Break**

10:30 – 12:00 Session III: Viral entry and early steps

Chaired by: Ulrike Protzer (Germany) and Koichi Watashi (Japan)

10:30-10:40 Real-time imaging of Hepatitis B virus reveals an early entry mechanism mediated by filopodia

Maika S. Deffieu









10:40 - 10:45 Q&A

10:45-10:55 CDC42 supports hepatitis B virus entry by fostering NTCP to plasma membrane and macropinocytosis

Yu Wei

10:55 - 12:00 Q&A

11:00-11:10 Diverse hepatitis B and D virus susceptibility in feline species determined by combined mutation in NTCP

Chisa Kobayashi

11:10 - 11:15 Q&A

11:15-11:25 Cathepsin F Regulates HBV-preS1/NTCP Interaction Facilitating HBV And HDV Entry Into Hepatocytes And Its Therapeutic Implications.

Abdulla A. Mahmoud

11:25 - 11:30 Q&A

11:30 – 11:40 Scavenger Receptor class F member 2 is an intracellular receptor for Hepatitis B virus Cong Li

11:40 - 11:45 Q&A

11:45 – 11:55 Disruption of HBV core protein dynamics and cccDNA maintenance by the capsid assembly modulator HAP_R01

Chunkyu Ko

11:55 - 12:00 Q&A

12:00 – 13:00 **Keynote Lecture I: Ang Cui** Assistant Professor, Systems Immunology, Harvard University

13:00 – 14:30 Lunch and "Meet the Speaker"

14:30 – 15:00 Introduction II: Immunology Maike Hoffmann (Germany)

15:00 – 16:00 **Session IV: Innate immunity**

Chaired by: Dimitra Peppa (UK) and Adam Gehring (Canada)

15:00 – 15:10 Macrophage Toll-like receptor 8 recognizes cleaved hepatitis B virus transcription products and activates NF-κB signaling

Jiatong Yin

15:10 - 15:15 Q&A

15:15-15:25 Early immune responses define Peg-IFN α -mediated treatment outcome in chronic hepatitis D virus infection

Helenie Kefalakes









15:25 - 15:30 Q&A

15:30-15:40 NK cell regulation constrains B cell immunity to the rapeutic vaccination in chronic HBV

Joseph McDowell

15:40 - 15:45 Q&A

15:45 – 15:55 Spatial and Single-Cell Transcriptomic Mapping Reveals Selective Disruption of Hepatocyte–Kupffer Cell Interactions in HBV/HDV Coinfection

Maria Saez-Palma

15:55 - 16:00 Q&A

16:00 – 16:30 **Coffee Break**

16:30 – 18:00 Session V: Adaptive immunity

Chaired by: Carolina Boni (Italy) and Georg Lauer (US)

16:30-16:40 Circadian control of HBV T-cell responses: Implications for optimising therapeutic vaccine timing

Alan Xiaodong Zhuang

16:40 - 16:45 Q&A

16:45-16:55 Role and mechanism of mCD100 in regulating the activation and differentiation of HBV-specific CD8 T cell

Mengxiao Zhao

16:55 - 17:00 Q&A

17:00 – 17:10 Immune Complexes of BJT-778 Enhance Cross-Presentation of HBsAg and Activation of CD8+ T Cells

Loghman Salimzadeh

17:10 - 17:15 Q&A

17:15-17:25 Lactate triggers HBV-Specific CD8+ T Cell Exhaustion through Mitophagy Suppression-Mediated Mitochondrial Dysfunction

Xiaoyi Liu

17:25 - 17:30 Q&A

17:30-17:40 **4-1BB Costimulation Restore Tfh1 Function to Augment HBV-Specific Humoral Immunity in Chronic Infection**

Yanchen Ma

17:40 - 17:45 Q&A

17:45 – 17:55 Th1-like CD4* T-cell responses are key drivers of an effective therapeutic vaccine against chronic hepatitis B

Jinpeng Su

17:55 - 18:00 Q&A









18:00 – 18:30 Updates from the Hepatitis B Foundation

Updates from ICE-HBV

18:30 – 20:00 **Poster Session I**

Wednesday, September 10, 2025

08:00 – 09:00 Parexel Rise & Shine Panel Discussion

09:00 – 10:30 Session VI: HBsAg clearance

Chaired by: Robert Thimme (Germany) and Nina Le Bert (Singapore)

9:00 – 9:10 The CD8 T cell transcriptional profile in chronic hepatitis B is shaped by antigenspecificity and is only partially corrected by HBsAg loss

Sara Doselli

9:10 - 9:15 Q&A

9:15 – 9:25 Clinical cure of chronic hepatitis B requires activation and perpetuation of a robust CD4+ Jody Baron

9:25 - 9:30 Q&A

9:30 – 9:40 Hepatitis B surface antigen loss is associated with reversal of B-cell dysregulation in Tarik Asselah

9:40 - 9:45 Q&A

9:45 – 9:55 Transcriptional landscapes of intrahepatic immunity in acute and chronic hepatitis B Martin Feuerherd

9:55 - 10:00 Q&A

 $10:\!00-10:\!10$ Distinct HBsAg-specific B cell phenotype precedes spontaneous HBsAg clearance in CHB

Lucy Cooper

10:10 - 10:15 Q&A

10:15-10:25 The intestinal microbiome regulates HBsAg seroconversion in mouse models of HBV Marta Grillo

10:25 - 10:30 Q&A











11:00 - 12:00	Poster Session II
---------------	-------------------

12:00 – 13:30 Session VII: Replication cycle

Chaired by: Christine Neuveut (France) and Maria Francesca Cortese (Spain)

12:00-12:10 Tracking the pathway of HBV DNA-containing virions using confocal and high-resolution microscopy

Vanessa Sarabia Vega

12:10 - 12:15 Q&A

12:15 – 12:25 HBV capsids engage FG phase of nuclear pores

Qiaoyi Li

12:25 - 12:30 Q&A

12:30 – 12:40 Cryo-EM analysis reveals cell-type-dependent phosphorylation patterns and structural Katie Culhane

12:40 - 12:45 Q&A

12:45 – 12:55 **How does HBV fall apart?**

Adam Zlotnick

12:55 - 13:00 Q&A

13:00-13:10 Drug-mediated transcriptional readthrough of HBV RNAs triggers antiviral effects in infected hepatocytes

Guillaume Giraud

13:10 - 13:15 Q&A

13:15 – 13:25 Direct RNA sequencing reveals m6A-dependent stabilization of hepatitis B virus RNA

Pei-Yi (Alma) Su

13:25 - 13:30 Q&A

13:30 – 14:30 Lunch and "Meet the Editor"

Eleni Kotsiliti, Fabien Zoulim, Haitao Guo, Matteo Iannacone, Peter Revil, Tobias Böttler

14:30 – 15:00 Introduction III: Therapy

Lefteris Michailidis (USA)

15:00 – 16:00 Session VIII: New perspectives in current treatments

Chaired by: Ashwin Balagopal (USA) and Rachel Wen-Juei Jeng (Taiwan)

 $15:00-15:10 \ \textbf{End-of-treatment biomarkers and HBV genotype predict severe biochemical flares}$

after Fleur Ballet

15:10 - 15:15 Q&A









15:15-15:25 Bulevirtide reduces HDV viral load and hepatocyte-derived innate immune responses in

Annika Volmari

15:25 - 15:30 Q&A

15:30-15:40 IB-001: A partial type I interferon agonist that exhibits potent anti-HBV activity with the potential for an improved safety profile

Yueh-Ming Loo

15:40 - 15:45 Q&A

15:45-15:55 Antiviral mode of action of IFN- α on Hepatitis Delta Virus (HDV) intracellular amplification

Elise Chabot

15:55 - 16:00 Q&A

16:00 – 16:30 Takeaway Coffee Break

16:30 – 19:00 Sightseeing Tour

Thursday, September 11, 2025

08:30 – 10:00 Session IX: Host-virus interplay

Chaired by: Thomas Tu (Australia) and Julie Lucifora (France)

8:30-8:40 HBV inhibits stress granule formation by hijacking core components of SGs into the nucleocapsids to maintain viral effective replication

Danjuan Lu

8:40 - 8:45 Q&A

8:45-8:55 HDV passively induces an innate immune-mediated specific refractoriness to IFN- α , but not IFN- λ treatment in infected hepatocytes

Claudie Eber

8:55 - 9:00 Q&A

9:00-9:10 Liver Mechanosignaling-Mediated HBV Control: A Non-Cytolytic Antiviral Mechanism with Implications for Therapeutic Response

Jieliang Chen

9:10 - 9:15 Q&A

9:15-9:25 A proteomic approach identifies COP9 signalosome as a key host factor in an early step of hepatitis B virus life cycle.

Karim Mouzannar









9:25 - 9:30 Q&A

9:30-9:40 The BAF Chromatin Remodeling Complex Regulates HBV cccDNA Transcriptional Activity

Rongjuan Pei

9:40 - 9:45 Q&A

9:45 – 9:55 Structural Determination of Subviral Particles of Hepatitis B Virus using Cryo-Electron Aditi Dhawan

9:55 - 10:00 Q&A

10:00 – 10:30 **Coffee Break**

10:30 – 12:00 Session X: Novel antiviral strategies

Chaired by: David Durantel (France) and Gregor Ebert (Germany)

10:30-10:40 Broad neutralizing efficacy of Brelovitug, a monoclonal antibody targeting HBsAg, against HBV and HDV infections across genotypes

Ronald Alcala

10:40 - 10:45 Q&A

10:45-10:55 Programmable RNA Sensor System for Targeted Elimination of Active HBV cccDNA and Integrated DNA Reservoirs

Jieliang Chen

10:55 - 11:00 Q&A

11:00 – 11:10 Preclinical profiling of ABI-6250, a first-in-class oral therapeutic candidate for chronic

Marc P. Windisch

11:10 - 11:15 Q&A

11:15 – 11:25 The CAM-E ALG-001075 potently reduces HBV cccDNA in preclinical experiments

Yannick Debing

11:25 - 11:30 Q&A

11:30 – 11:40 Antisense oligonucleotide-based strategy to target hepatitis delta virus infections

Julie Lucifora

11:40 - 11:45 Q&A

11:45 – 11:55 Adenine Base Editing of HBx ORF to inhibit HBV replication

Emmanuel Combe

11:55 – 12:00 Q&A

12:00 – 13:00 **Keynote Lecture II: Angelo Lombardo, PhD,** Assistant Professor, Università Vita-Salute San Raffaele,

Milan, Italy









13:00 – 14:30 Lunch and "Meet the Speaker"

14:30 – 16:00 Session XI: Novel immunotherapeutic strategies

Chaired by: Ivana Carey (UK) and Sabela Lens (Spain)

14:30-14:40 Epitope-mismatched helper T cells induced by BRII-179 therapeutic vaccination break anti-HBs humoral tolerance in CHB patients

Nina Le Bert

14:40 - 14:45 Q&A

14:45 – 14:55 A multivalent mRNA-LNP therapeutic vaccine with broad cross-genotype immunogenicity

Yanbo Sun

14:55 - 15:00 Q&A

15:00-15:10 Genetic immunotherapy against chronic Hepatitis D Virus infection

Matti Sallberg

15:10 - 15:15 Q&A

15:15 – 15:25 Identification and preclinical evaluation of a potent HLA-A*24:02-restricted, HBV envelope-specific T cell receptor for adoptive T cell therapy

Nina Kallin

15:25 - 15:30 Q&A

15:30-15:40 HBV immune checkpoint receptor CD33 (Siglec-3) is a promising therapeutic target for chronic hepatitis B infection

Shie Liang Hsieh

15:40 - 15:45 Q&A

15:45-15:55 Testing the safety and anti-HBV efficacy of formulated RIG-I agonist RNA in a rhesus macaque model

Sreya Biswas

15:55 – 16:00 Q&A

16:00 – 16:30 **Coffee Break**

16:30 – 18:00 Research without Borders

18:00 – 19:00 Session XII: Pathogenesis

Chaired by: Janine Kah (Germany) and Antonio Bertoletti (Singapore)

18:00 – 18:10 Tumor Size-Dependent Endothelial Reprogramming Limits CD8+ T Cell Immune

Carlotta Tacconi

18:10 - 18:15 Q&A









18:15 – 18:25 Selective depletion of HBsAg-specific B cells in paediatric chronic hepatitis B infection

Sabela Lens

18:25 – 18:30 Q&A

18:30-18:40 Spatial analysis of the chronic hepatitis B and D liver reveals new aspects of viral Nadina Wand

18:40 - 18:45 Q&A

18:45 – 18:55 Circulating Capsid-Antibody-Complexes (CACs) drive intrahepatic complement Xiaonan Zhang

18:55 - 19:00 Q&A

19:00 - 19:30 Farewell and 2026 International HBV Meeting Presentation

20:00 – 23:00 Networking Dinner

Friday, September 12, 2025

08:30 – 11:30 **ICE-HBV Symposium**

Welcome & Opening Remarks Fabien Zoulim and Teresa Pollicino (5 min)

1)The viral reservoir in the liver (15 min: 12 min + 3 min discussion) Maura Dandri (Hamburg, Germany)

2)Genome editing technologies (60 min: 10 min + 5 min questions for each talk)

- Excision CRISPR/Cas9 approach: EBT-107 for HBV. Ryo Takeuchi (Excision, U.S.)
- Precision Arcus technology: PBGENE-HBV. Emily Harrison (Precision, U.S.)
- Beam base editors: A and C Base editors for HBV and HDV. Anuj Kumar (Lyon, France)
- HBV RNA targeting with Cas13. Laura McCoullough (Melbourne, Australia)

Coffee break (15 min)

- 3) Epigenome editing technologies (45 min: 10 min + 5 min questions for each talk)
- nChroma technology for HBV DNA Methylation: CRMA-1001 for HBV. Sarah Voytek (nChroma Bio, U.S.)
- Tune technology for HBV DNA Methylation: Tune-401 for HBV. Brian Cosgrove (Tune Tx, U.S.)
- EPIREG: Next-gen Epigenetic Modulator for HBV Eradication through direct silencing of ccDNAtranscription. Yidi Sun (Epigenic, China)











- 4) Knowledge gaps to advance clinical development of gene and epigenome editing (10 min) Fabien Zoulim (Lyon,France) (introduction to the roundtable)
- 5) Round table discussion (30 min): Co-chairs, Speakers and with the contribution of Markus Cornberg (MHH, CiiMHannover, Germany) and Kosh Agarval (Kings College hospital, London, U.K.)

Closing Remarks (5 min) - Fabien Zoulim and Teresa Pollicino